O	0	6	Effect
O	7	9	of
B-intervention	10	17	topical
I-intervention	18	29	microporous
I-intervention	30	44	polysaccharide
I-intervention	45	56	hemospheres
O	57	59	on
O	60	63	the
O	64	72	duration
O	73	76	and
O	77	83	amount
O	84	86	of
O	87	92	fluid
O	93	101	drainage
O	102	111	following
O	112	122	mastectomy
O	122	123	:
O	124	125	a
O	126	137	prospective
O	138	148	randomized
O	149	157	clinical
O	158	163	trial
O	163	164	.

B-condition	165	171	Seroma
I-condition	172	181	formation
O	182	184	is
O	185	188	the
O	189	193	most
O	194	200	common
O	201	213	complication
O	214	219	after
O	220	230	mastectomy
O	231	234	and
O	235	241	places
O	242	250	patients
O	251	253	at
O	254	258	risk
O	259	261	of
O	262	272	associated
O	273	284	morbidities
O	284	285	.

O	286	297	Microporous
O	298	312	polysaccharide
O	313	324	hemospheres
O	325	326	(
O	326	329	MPH
O	329	330	)
O	331	339	consists
O	340	342	of
O	343	354	hydrophilic
O	354	355	,
O	356	361	plant
O	362	367	based
O	367	368	,
O	369	383	polysaccharide
O	384	393	particles
O	394	397	and
O	398	400	is
O	401	410	currently
O	411	415	used
O	416	418	as
O	419	421	an
O	422	432	absorbable
O	433	443	hemostatic
O	444	449	agent
O	449	450	.

O	451	453	An
O	454	460	animal
O	461	466	model
O	467	477	evaluating
O	478	481	MPH
O	482	485	and
O	486	492	seroma
O	493	502	formation
O	503	508	after
O	509	519	mastectomy
O	520	524	with
O	525	533	axillary
O	534	539	lymph
O	540	544	node
O	545	555	dissection
O	556	562	showed
O	563	564	a
O	565	576	significant
O	577	585	decrease
O	586	588	in
O	589	595	seroma
O	596	602	volume
O	602	603	.

O	604	609	Study
O	610	613	aim
O	614	617	was
O	618	620	to
O	621	629	evaluate
O	630	637	topical
O	638	641	MPH
O	642	644	on
O	645	648	the
O	649	653	risk
O	654	656	of
O	657	661	post
O	661	662	-
O	662	672	mastectomy
O	673	679	seroma
O	680	689	formation
O	690	692	as
O	693	701	measured
O	702	704	by
O	705	710	total
O	711	716	drain
O	717	723	output
O	724	727	and
O	728	733	total
O	734	739	drain
O	740	744	days
O	744	745	.

O	746	757	Prospective
O	758	768	randomized
O	769	775	single
O	775	776	-
O	776	783	blinded
O	784	792	clinical
O	793	798	trial
O	799	801	of
B-eligibility	802	810	patients
I-eligibility	811	821	undergoing
I-eligibility	822	832	mastectomy
I-eligibility	833	836	for
I-eligibility	837	840	the
I-eligibility	841	850	treatment
I-eligibility	851	853	of
I-eligibility	854	860	breast
I-eligibility	861	867	cancer
O	867	868	.

O	869	872	MPH
O	873	876	was
O	877	884	applied
O	885	887	to
O	888	891	the
O	892	900	surgical
O	901	905	site
O	906	908	in
O	909	912	the
O	913	918	study
O	919	924	group
O	925	928	and
B-control	929	931	no
I-control	932	943	application
I-control	944	946	in
I-control	947	950	the
I-control	951	958	control
I-control	959	964	group
O	964	965	.

B-total-participants	966	971	Fifty
O	972	980	patients
O	981	985	were
O	986	994	enrolled
O	994	995	;
O	996	1001	eight
O	1002	1006	were
O	1007	1015	excluded
O	1016	1019	due
O	1020	1022	to
O	1023	1030	missing
O	1031	1035	data
O	1035	1036	.

B-total-participants	1037	1042	Forty
I-total-participants	1042	1043	-
I-total-participants	1043	1046	two
O	1047	1055	patients
O	1056	1060	were
O	1061	1070	evaluated
O	1070	1071	,
O	1072	1079	control
O	1080	1081	(
O	1081	1082	n
O	1083	1084	=
B-control-participants	1085	1087	21
O	1087	1088	)
O	1089	1091	vs
O	1091	1092	.
O	1093	1096	MPH
O	1097	1098	(
O	1098	1099	n
O	1100	1101	=
B-intervention-participants	1102	1104	21
O	1104	1105	)
O	1105	1106	.

O	1107	1109	No
O	1110	1120	difference
O	1121	1124	was
O	1125	1135	identified
O	1136	1143	between
O	1144	1147	the
O	1148	1151	two
O	1152	1158	groups
O	1159	1168	regarding
O	1169	1181	demographics
O	1181	1182	,
O	1183	1188	tumor
O	1189	1194	stage
O	1194	1195	,
O	1196	1201	total
O	1202	1207	drain
O	1208	1212	days
O	1212	1213	,
O	1214	1219	total
O	1220	1225	drain
O	1226	1232	output
O	1232	1233	,
O	1234	1240	number
O	1241	1243	of
O	1244	1250	clinic
O	1251	1257	visits
O	1257	1258	,
O	1259	1261	or
O	1262	1274	complication
O	1275	1280	rates
O	1280	1281	.

O	1282	1284	On
O	1285	1286	a
O	1287	1293	subset
O	1294	1302	analysis
O	1302	1303	,
O	1304	1308	body
O	1309	1313	mass
O	1314	1319	index
O	1320	1321	(
O	1321	1324	BMI
O	1324	1325	)
O	1326	1333	greater
O	1334	1338	than
O	1339	1341	30
O	1342	1345	was
O	1346	1356	identified
O	1357	1359	as
O	1360	1362	an
O	1363	1374	independent
O	1375	1379	risk
O	1380	1386	factor
O	1387	1390	for
O	1391	1395	high
B-outcome	1396	1401	drain
I-outcome	1402	1408	output
O	1408	1409	.

B-outcome	1410	1414	Post
I-outcome	1415	1418	hoc
I-outcome	1419	1427	analyses
I-outcome	1428	1430	of
I-outcome	1431	1434	MPH
O	1435	1446	controlling
O	1447	1450	for
O	1451	1454	BMI
O	1455	1459	also
O	1460	1468	revealed
O	1469	1471	no
O	1472	1483	statistical
O	1484	1494	difference
O	1494	1495	.

O	1496	1502	Unlike
O	1503	1506	the
O	1507	1511	data
O	1512	1521	presented
O	1522	1524	in
O	1525	1527	an
O	1528	1534	animal
O	1535	1540	model
O	1540	1541	,
O	1542	1544	no
O	1545	1555	difference
O	1556	1559	was
O	1560	1572	demonstrated
O	1573	1575	in
O	1576	1579	the
O	1580	1588	duration
O	1589	1592	and
O	1593	1601	quantity
O	1602	1604	of
O	1605	1619	serosanguinous
O	1620	1628	drainage
O	1629	1636	related
O	1637	1639	to
O	1640	1643	the
O	1644	1647	use
O	1648	1650	of
O	1651	1654	MPH
O	1655	1657	in
O	1658	1666	patients
O	1667	1677	undergoing
O	1678	1688	mastectomy
O	1689	1692	for
O	1693	1696	the
O	1697	1706	treatment
O	1707	1709	of
O	1710	1716	breast
O	1717	1723	cancer
O	1723	1724	.

O	1725	1728	BMI
O	1729	1736	greater
O	1737	1741	than
O	1742	1744	30
O	1745	1748	was
O	1749	1759	identified
O	1760	1762	as
O	1763	1765	an
O	1766	1777	independent
O	1778	1782	risk
O	1783	1789	factor
O	1790	1793	for
O	1794	1798	high
O	1799	1804	drain
O	1805	1811	output
O	1812	1815	and
O	1816	1820	this
O	1821	1825	risk
O	1826	1829	was
O	1830	1833	not
O	1834	1842	affected
O	1843	1845	by
O	1846	1849	MPH
O	1850	1853	use
O	1853	1854	.

O	1855	1866	NCT03647930
O	1866	1867	,
O	1868	1883	retrospectively
O	1884	1894	registered
O	1895	1897	08
O	1897	1898	/
O	1898	1902	2018
O	1902	1903	.
